M&A / Deals UCB cuts $1.15bn deal to buy epilepsy biotech Neurona PharmaphorumUCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy. M&A / DealsNeuroscienceRead full story Post navigation Previous: Magazine: Digital twins become the new battleground for CDMOsNext: UCB to purchase Neurona and NRTX-1001 for $1.15bn Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
